POST SUMMARY: Spending on cancer medicines represents less than 1 percent of all health care spending for all diseases —$25.9 billion out of $2,800 billion. Cancer medicines represent 20 percent of total spending on cancer care. But don’t let facts get in the way of a good media story.
POST SUMMARY: The current model of the way cancer drugs are prices is unsustaianable and innovation is needed both to develop new drugs and price them in a way that ensures the drug is priced on “the value” it brings to patients.
POST SUMMARY: Physicians do not prescribe an Rx because they are getting paid by drug companies. Actually, they are more likely to prescribe a certain product because of insurance companies and managed care incentives.
POST SUMMARY: Low levels of adherence are extremely expensive. The main take home point of a CVS Health study is that we need to look more closely at drug adherence in the community setting, not just for disease management, but for cost containment as well.
POST SUMMARY:Via the WSJ: The first of a promising new class of cancer drugs went on sale in Japan this week at an average annual cost of $143,000 a patient, a harbinger of hefty prices the new drugs are expected to command in the U.S. and Europe in coming months. Bristol-Myers, which plans to market nivolumab in the U.S. if the FDA clears it for sale, declined to say how much it will charge. A spokeswoman said the company prices its medicines based on “the value they deliver to patients and society, the scientific innovation they represent and the investment required to support” drug research-and-development.
POST SUMMARY: 70 percent of all Americans are on at least one prescription drug, and 20 percent of all Americans are on at least five prescription drugs and according to the CDC, approximately 9 out of every 10 Americans that are at least 60 years old say that they have taken at least one prescription drug within the last month. Are we treating patients with an Rx when they might need other forms of treatments?